Long-Term Dosing of Eliquis for Unprovoked Pulmonary Embolism
For long-term anticoagulation of unprovoked pulmonary embolism after completing at least 6 months of initial treatment, the appropriate dose of apixaban (Eliquis) is 2.5 mg twice daily.
Dosing Algorithm
Initial Treatment Phase (First 6 Months)
- Days 1-7: Apixaban 10 mg twice daily
- After Day 7 through Month 6: Apixaban 5 mg twice daily 1
Extended/Long-Term Phase (After 6 Months)
- Standard dose for extended therapy: Apixaban 2.5 mg twice daily 1
This reduced-dose regimen is FDA-approved specifically for "reduction in the risk of recurrence of DVT and PE" after completing at least 6 months of treatment 1.
Evidence Supporting Extended Therapy
Unprovoked PE warrants extended anticoagulation. The 2021 CHEST guidelines strongly recommend offering extended-phase anticoagulation with a DOAC for patients with unprovoked VTE 2. The 2016 CHEST guidelines similarly suggest extended anticoagulant therapy over stopping at 3 months for first unprovoked PE with low or moderate bleeding risk 3.
The rationale is clear: unprovoked PE carries substantial recurrence risk after stopping anticoagulation, while extended therapy dramatically reduces this risk. The AMPLIFY trial demonstrated apixaban's efficacy with 10 mg twice daily for 7 days followed by 5 mg twice daily, showing non-inferiority to warfarin with superior bleeding profile (0.6% vs 1.8% major bleeding) 4, 3.
Reduced-Dose vs Full-Dose for Extended Therapy
The 2021 CHEST guidelines suggest using reduced-dose apixaban (2.5 mg twice daily) over full-dose (5 mg twice daily) for extended-phase anticoagulation 2. The 2020 ASH guidelines similarly suggest either standard or lower-dose DOAC is acceptable, with lower-dose options including apixaban 2.5 mg twice daily 5.
The evidence shows reduced-dose apixaban maintains efficacy while potentially improving the risk-benefit ratio. Studies comparing reduced versus standard doses found:
- No significant difference in recurrent VTE
- No significant difference in major bleeding
- Similar mortality rates 5
The reduced dose provides adequate protection against recurrence while minimizing bleeding risk—a critical consideration for indefinite therapy.
Key Clinical Considerations
Reassessment Requirements
Extended anticoagulation should be reevaluated at least annually and with significant health status changes 2. This is not "set it and forget it" therapy—bleeding risk, patient preference, and clinical circumstances evolve.
Bleeding Risk Stratification
- Low/moderate bleeding risk: Extended therapy strongly favored 6, 2
- High bleeding risk: Consider stopping at 3 months, though extended therapy may still be reasonable 6
Common Pitfalls to Avoid
- Don't use the 5 mg twice daily dose for extended therapy—this is the acute treatment dose, not the extended prevention dose
- Don't confuse atrial fibrillation dosing (which uses 5 mg or 2.5 mg twice daily based on age/weight/creatinine criteria) with VTE extended therapy dosing (which uses 2.5 mg twice daily universally) 1
- Don't stop at 3 or 6 months automatically—unprovoked PE requires individualized assessment for extended therapy
Drug Interactions
Avoid combining apixaban 2.5 mg twice daily with combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir). For patients on 5 mg twice daily, reduce dose by 50% with these inhibitors 1.
Renal Considerations
The FDA label specifies avoiding apixaban with severe renal impairment (CrCl <15 mL/min), though patients with CrCl <25 mL/min were excluded from trials 4.